The role of apolipoprotein E polymorphism in improving dyslipidemia in obese adolescents following physical exercise and National Cholesterol Education Program Step II intervention

2015 ◽  
Vol 28 (5-6) ◽  
Author(s):  
Lanny C. Gultom ◽  
Damayanti R. Sjarif ◽  
Herawati A. Sudoyo ◽  
Muchtaruddin Mansyur ◽  
Sri Rezeki S. Hadinegoro ◽  
...  
Keyword(s):  
Physical Exercise ◽  
Apolipoprotein E ◽  
Blood Lipid ◽  
Lifestyle Changes ◽  
Lipid Lowering ◽  
Exercise Interventions ◽  
Obese Adolescents ◽  
Lipid Lowering Drugs ◽  
Apo E ◽  
Before And After

AbstractLifestyle changes are important factors for managing dyslipidemia before considering blood lipid-lowering drugs. However, genetic factors can influence the response outcome.We aimed to determine a dyslipidemia management strategy in obese adolescents.: A total of 60 dyslipidemic obese adolescents received physical exercise and the NCEP step II diet for 28 days. Apolipoprotein E (apo E) genotypes and blood lipid levels were compared before and after interventions.The apoApo E alleles might influence improvement in lipid profiles after diet and exercise interventions. These results could inform personalized dyslipidemia management in obese adolescents, to determine which subjects would benefit from blood lipid-lowering drugs.

scholarly journals The Impact of Changes in Population LDL-C Levels on LDL-C Control in Patients After PCI in China: A Retrospective Cohort Study

2020 ◽  
Author(s):  
Huan Liu ◽  
Zhipeng Zhou ◽  
Yanqing Wu ◽  
Jingsong Xu
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Coronary Intervention ◽  
Lifestyle Changes ◽  
Treatment Goal ◽  
Lipid Lowering ◽  
Lipid Control ◽  
The Impact

Abstract BANKGROUND: Mortality from coronary artery disease continues to rise, and secondary prevention and treatment are particularly important. OBJECTIVE: The objective of this study is to evaluate low-density lipoprotein cholesterol (LDL-C) levels in patients after percutaneous coronary intervention (PCI), to describe how treatment outcomes for individual patients changed over time and to examine the potential impact of lipid control rates through population LDL-C levels changes.METHODS: This retrospective study was conducted in patients who underwent PCI between July 2017 and June 2019. The main results included LDL-C levels after PCI. To assess the outcome of prevention, three separate measures of LDL-C were considered: baseline, first follow-up, and final follow-up, and LDL-C control rates were analyzed according to different guidelines. we examine the impact of 0.1mmol/l decreases or increases in population LDL-C levels on LDL-C control.RESULTS: Data were analyzed for 423 patients (mean age, 62 ±10 years), and the baseline LDL-C level was 3.11 ± 0.99 mmol/l. 51.5% of the patients achieved the Chinese Lipids Guidelines treatment goal, 22% and 11.6% of the patients achieved the 2016 ESC Lipids Guidelines and 2019 ESC Lipids Guidelines treatment goal at the final follow-up period respectively. LDL-C levels fluctuated during the follow-up period, and the long-term maintenance results could not be guaranteed after PCI. Population LDL-C levels changes in lifestyle could have a very large impact on LDL-C control in China.CONCLUSION: LDL-C control with statins is not ideal in patients after PCI, which is far from the requirements of the latest guidelines. Although clinicians understand the lipid-lowering effect of statins, they should not give up active lifestyle changes, and should strengthen the comprehensive management of blood lipid control.

scholarly journals Blood Lipid Levels in Patients with Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Hang Zhao ◽  
An Song ◽  
Yong Li ◽  
Licui Qi ◽  
Chong Zheng ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Relevant Information ◽  
Lipid Lowering ◽  
Cochrane Library ◽  
Lipid Levels ◽  
Lipid Lowering Drugs ◽  
Blood Lipid Levels

Abstract Background: Considering the controversial relationship between blood lipid levels and osteopenia and osteoporosis (OP), we performed this meta-analysis.Methods: Using specific keywords and related words, we searched PubMed, Embase, and Cochrane Library databases. The Newcastle-Ottawa Scale form was used to evaluate the quality of the literature. According to the inclusion and exclusion criteria, we systematically screened the literature to extract relevant information and data. Revman 5.3 and Stata 13.0 software were used for statistical analysis. Results were expressed as the mean difference and 95% confidence interval. The heterogeneity test was conducted according to I2 and Q tests. Egger’s test was used to quantitatively evaluate publication bias.Results: This analysis involved 12 studies and included 12,395 subjects. The quality of the literature was acceptable. Among subjects who were not taking lipid-lowering drugs, total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the osteopenia were not significantly increased/decreased. There were no significant differences in LDL-C in postmenopausal women in osteopenia. TG was unchanged in the OP group in subjects without taking lipid-lowering drugs. HDL-C was elevated in OP group but not in osteopenia group in all subjectsConclusions: HDL-C was elevated in patients with OP.

Importance of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia and atherosclerosis

2019 ◽  
pp. 40-52
Author(s):  
Maksim Maksimov ◽  
Anastasia Shikaleva ◽  
Aleksandra Kuchaeva
Keyword(s):  
Clinical Studies ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Low Density ◽  
Pcsk9 Inhibitors ◽  
Lipid Lowering Drugs ◽  
Antibody Preparations

Representatives of different groups of lipid-lowering drugs may have some differences in the nature and severity of the effect on the blood lipid spectrum. A new class of drugs, PCSK9 inhibitors, whose activity is associated with a protein involved in the control of low density lipoprotein receptors, has recently appeared. In clinical practice, this group is represented by monoclonal antibody preparations evolocumab and alirocumab. PCSK9 inhibitors are promising drugs for use in combination lipid-lowering therapy, which so far, given the results of clinical studies, can be recommended in the third place after statins and ezetimibe. In clinical studies, it was shown that alirocoumab and evolocumab alone or in combination with statins and/or other lipid-lowering drugs significantly reduce cholesterol levels in low density lipoproteins – by an average of 60%, depending on the dose.

scholarly journals Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study

2010 ◽  
Vol 3 (5) ◽  
pp. 462-467 ◽  
Author(s):  
Marguerite R. Irvin ◽  
Edmond K. Kabagambe ◽  
Hemant K. Tiwari ◽  
Laurence D. Parnell ◽  
Robert J. Straka ◽  
...  
Keyword(s):  
Apolipoprotein E ◽  
Lipid Lowering ◽  
Fenofibrate Treatment ◽  
Before And After

scholarly journals Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases

2021 ◽  
Vol 50 (6) ◽  
pp. 474-480
Author(s):  
Yuexi Wang ◽  
Xiaohong Du ◽  
Ruifen Zhao ◽  
Juan Niu ◽  
Haixu Wang ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Apolipoprotein E ◽  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipid Lowering ◽  
Apoe Ε4 ◽  
Atherosclerotic Cardiovascular Diseases ◽  
Apoe Genotypes

Introduction: Apolipoprotein E (APOE) gene is a promising candidate for the diagnosis of hyperlipoproteinaemia and atherosclerosis. Polymorphisms in APOE have been reported to result in differential efficacies of statins in atherosclerotic cardiovascular diseases. Method: We classified APOE genotypes of 225 patients treated with atorvastatin and analysed the relationship between genotypes and blood lipid levels. Results: The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly lower in APOE ε4 than APOE ε3 carriers. Levels of TC and LDL-C decreased significantly after 1 month of atorvastatin treatment. Statins have a higher significant effect in reducing TC and LDL-C levels in APOE ε4 genotype. Conclusion: Polymorphism in APOE is related to the efficacy of atorvastatin in reducing the levels of TC and LDL-C. Keywords: Apolipoprotein E, lipid-lowering efficacy, polymorphism, statin, total cholesterol

Abstract P127: Dose-dependent Effects of Comprehensive Lifestyle Changes on Blood Lipid Levels: Results From the PREMIER Trial

Circulation ◽  
2017 ◽  
Vol 135 (suppl_1) ◽  
Author(s):  
Ramzi Dudum ◽  
Stephen P Juraschek ◽  
Lawrence J Appel
Keyword(s):  
Sodium Intake ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lifestyle Changes ◽  
Lipid Lowering ◽  
Behavioral Counseling ◽  
Calorie Diet ◽  
Cv Disease ◽  
Dose Dependent

Introduction: Low-density lipoprotein (LDLc) is a major risk factor for cardiovascular (CV) disease. While comprehensive lifestyle change (CLC) lowers LDLc, little is known about how CLC adherence affects LDLc levels. Hypothesis: The PREMIER trial demonstrated CLC reduced LDLc levels. We hypothesized those undergoing CLC will exhibit dose dependent reductions in LDLc proportional to the number of intervention sessions attended. Methods: PREMIER was a multicenter randomized trial in adults with pre-hypertension or stage 1 hypertension. The current analyses were limited to participants randomized to CLC interventions, excluding those who were assigned to control, those on lipid-lowering medication, or those missing follow-up lipid data. One intervention, “Established” (Est.), was a CLC that emphasized increased physical activity, weight reduction, reduced sodium intake, and a reduced fat/calorie diet. A second CLC intervention, “Established+DASH” (Est.+DASH), also included counseling on the DASH diet. Behavioral counseling was delivered via 18 sessions in the first 6 months and 15 sessions in the following 12 months (total 33 sessions). Results: Among the 450 participants, mean age was 50.4, 63% were women, and 31% were black. Baseline LDLc was 134 mg/dL in Est. and 134.8 mg/dL in Est.+DASH. Mean attendance in the first 6 months was 14.2 sessions in Est. and 14.6 in Est.+DASH, and in the last 12 months was 9.6 sessions in Est. and 10.1 sessions in Est.+DASH. There was no difference in attendance by intervention. After adjustment for factors associated with LDLc, every 10 CLC sessions were associated with a 6 mg/dL (P=0.003) lower LDLc ( Table ). This association was attenuated when adjusted for weight change. Similar patterns were noted for triglycerides and total cholesterol. Conclusions: Better attendance at CLC sessions was associated with larger reductions in LDLc over an 18 month period with evidence that weight loss mediated this relationship.

Risk factor management: antiatherogenic therapies

2009 ◽  
Vol 16 (2_suppl) ◽  
pp. S29-S36 ◽  
Author(s):  
Stephan Gielen ◽  
Marcus Sandri ◽  
Gerhard Schuler ◽  
Daniel Teupser
Keyword(s):  
Risk Factor ◽  
Physical Exercise ◽  
Lifestyle Changes ◽  
Lipid Lowering ◽  
Western World ◽  
Risk Factor Management ◽  
Risk Factor Modification ◽  
Target Values ◽  
Regular Physical Exercise ◽  
Factor Modification

Despite the advances in interventional techniques, the management of stable atherosclerosis remains the domain of optimal guideline-oriented therapy. Recent studies on the effects of aggressive lipid lowering on atheroma volume changes using intravascular ultrasound indicate that it is possible to achieve atherosclerosis regression by reaching low-density lipoprotein (LDL) levels less than 75 mg/dl. The pleiotropic anti-inflammatory effects of statins contribute to the reduction of cardiovascular (CV) event observed with aggressive lipid lowering. As a second important strategy to prevent disease progression, lifestyle changes with regular physical exercise are capable of halting the atherosclerotic process and reducing angina symptoms and CV events. Optimal medical therapy, a healthy lifestyle with regular physical exercise, and coronary interventions are not mutually exclusive treatment strategies. Over the last few decades, both have proved to be effective in significantly reducing the CV mortality in the Western world. However, risk factor modification contributed to at least half the effect in the reduction of CV mortality. This figure provides an estimate of what could be achieved if we were to take risk factor modification more seriously – especially in the acute care setting. The knowledge is there: today we have a better understanding on how to stop progression and even induce regression of atherosclerosis. Much research still needs to be done and will be done. In the meantime, however, our primary focus should lie in implementing what is already known. In addition, it is essential not just to treat CV risk factors, but also to treat them to achieve the target values as set by the guidelines of European Society of Cardiology.

Sign in / Sign up

Export Citation Format

Share Document